“Some times I get up and can’t consider how far we’ve come,” claimed Dr. Doblin, 67, who now oversees the Multidisciplinary Affiliation for Psychedelic Studies, a multimillion greenback research and advocacy empire that employs a hundred thirty neuroscientists, pharmacologists and regulatory experts Doing work to put the groundwork for the